|
Unmet medical need
|
Extending treatment options in new indication with unmet medical need
|
Reduction of the unmet medical need for patients in a new indication due to additional therapeutical value
|
|
Individual needs/special needs of patient (sub)population
|
Reduction of the unmet medical need in patients with special needs in the original indication (e.g., treatment resistant patients, vulnerable patients, etc.)
|
|
Health gain (measured by health care professionals)
|
Efficacy/Effectiveness
|
Improved clinical outcomes of a pharmaceutical treatment (e.g., extending survival, stabilizing disease, improving treatment response, etc.) in trial and real-world settings
|
|
Patient safety and tolerability
|
Improved safety and/or tolerability of the pharmaceutical treatment
|
|
Patient Reported Outcomes
|
Patient experience related to the therapy
|
Improved patient's satisfaction, acceptance, convenience with the pharmaceutical therapy
|
|
Adherence and persistence
|
Improved adherence and/or persistence of patients with the prescription guidelines (including duration, timing, dosage and frequency of medication use)
|
|
Quality of life
|
Improved health-related quality of life reported by patients
|
|
Burden on households
|
Patient's economic burden
|
Improved productivity of patients and/or reduced health and non-health care resource use (such as travel time) covered by patients
|
|
Economic and health burden on informal caregiver
|
Improved quality of life of family caregivers and/or reduced financial or non-financial burden on households
|
|
Burden on health care system
|
Health care resource utilization, costs or efficiency
|
Reduced utilization of health care cost and/or resources
|
|
Technological improvement with logistical considerations
|
Improved stability and/or shelf life of pharmaceuticals through technological improvement
|
